Compare Aurobindo Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TORRENT PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TORRENT PHARMA AUROBINDO PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 14.3 59.8 23.9% View Chart
P/BV x 3.1 6.3 49.1% View Chart
Dividend Yield % 0.4 0.8 49.8%  

Financials

 AUROBINDO PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
TORRENT PHARMA
Mar-18
AUROBINDO PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs8091,550 52.2%   
Low Rs5041,144 44.1%   
Sales per share (Unadj.) Rs281.1354.7 79.2%  
Earnings per share (Unadj.) Rs41.440.1 103.2%  
Cash flow per share (Unadj.) Rs50.964.2 79.2%  
Dividends per share (Unadj.) Rs2.5014.00 17.9%  
Dividend yield (eoy) %0.41.0 36.6%  
Book value per share (Unadj.) Rs199.4273.1 73.0%  
Shares outstanding (eoy) m585.88169.22 346.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.8 61.5%   
Avg P/E ratio x15.933.6 47.2%  
P/CF ratio (eoy) x12.921.0 61.5%  
Price / Book Value ratio x3.34.9 66.8%  
Dividend payout %6.034.9 17.3%   
Avg Mkt Cap Rs m384,630227,897 168.8%   
No. of employees `00017.314.7 117.9%   
Total wages/salary Rs m21,30811,353 187.7%   
Avg. sales/employee Rs Th9,500.74,083.0 232.7%   
Avg. wages/employee Rs Th1,229.4772.3 159.2%   
Avg. net profit/employee Rs Th1,397.9461.3 303.0%   
INCOME DATA
Net Sales Rs m164,66660,021 274.3%  
Other income Rs m1,0202,988 34.1%   
Total revenues Rs m165,68663,009 263.0%   
Gross profit Rs m37,71813,493 279.5%  
Depreciation Rs m5,5804,086 136.6%   
Interest Rs m7773,085 25.2%   
Profit before tax Rs m32,3809,310 347.8%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1832,529 323.6%   
Profit after tax Rs m24,2296,781 357.3%  
Gross profit margin %22.922.5 101.9%  
Effective tax rate %25.327.2 93.0%   
Net profit margin %14.711.3 130.2%  
BALANCE SHEET DATA
Current assets Rs m121,87852,623 231.6%   
Current liabilities Rs m86,80652,022 166.9%   
Net working cap to sales %21.31.0 2,125.3%  
Current ratio x1.41.0 138.8%  
Inventory Days Days130120 108.6%  
Debtors Days Days6876 89.7%  
Net fixed assets Rs m81,03785,016 95.3%   
Share capital Rs m586846 69.2%   
"Free" reserves Rs m116,21845,376 256.1%   
Net worth Rs m116,80446,222 252.7%   
Long term debt Rs m4,51241,115 11.0%   
Total assets Rs m211,052142,432 148.2%  
Interest coverage x42.74.0 1,061.8%   
Debt to equity ratio x00.9 4.3%  
Sales to assets ratio x0.80.4 185.1%   
Return on assets %11.86.9 171.0%  
Return on equity %20.714.7 141.4%  
Return on capital %27.414.2 192.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72714,580 553.7%   
Fx outflow Rs m34,7003,600 963.9%   
Net fx Rs m46,02710,980 419.2%   
CASH FLOW
From Operations Rs m19,5488,942 218.6%  
From Investments Rs m-19,570-47,070 41.6%  
From Financial Activity Rs m8,64234,174 25.3%  
Net Cashflow Rs m8,922-3,655 -244.1%  

Share Holding

Indian Promoters % 54.1 71.5 75.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 7.0 113.2%  
FIIs % 27.7 12.6 219.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.8 115.9%  
Shareholders   69,601 26,511 262.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS